Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: a comparison of response by organ class from the randomized, phase 3 REACH2 study-MedSci.cn

Ruxolitinib versus best available therapy in patients with steroid-refractory acute graft-versus-host disease: a comparison of response by organ class from the randomized, phase 3 REACH2 study

Mohty, M; Zeiser, R; Galvin, J; Wilke, C; Tian, C; Bhatt, V

BONE MARROW TRANSPLANTATION, 2022; 57 (SUPPL 1): 39

科室
- - 订阅+
  - 更多科室
工具
服务